11/20
08:00 am
rvty
Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK
Low
Report
Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK
11/19
08:00 am
rvty
Revvity to Present at 7th Annual Evercore ISI HealthCONx Conference
Low
Report
Revvity to Present at 7th Annual Evercore ISI HealthCONx Conference
11/19
08:00 am
rvty
Scale Biosciences and Revvity’s BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells
Low
Report
Scale Biosciences and Revvity’s BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells
11/18
08:00 am
rvty
Revvity to Host Investor Day and Updates Organizational Structure to Reflect Recent Transformation
Low
Report
Revvity to Host Investor Day and Updates Organizational Structure to Reflect Recent Transformation
11/5
02:32 pm
rvty
Revvity, Inc. (NYSE: RVTY) had its price target raised by analysts at TD Cowen from $141.00 to $144.00. They now have a "buy" rating on the stock.
Low
Report
Revvity, Inc. (NYSE: RVTY) had its price target raised by analysts at TD Cowen from $141.00 to $144.00. They now have a "buy" rating on the stock.
11/5
01:49 pm
rvty
Revvity, Inc. (NYSE: RVTY) had its price target raised by analysts at Raymond James from $144.00 to $146.00. They now have an "outperform" rating on the stock.
Low
Report
Revvity, Inc. (NYSE: RVTY) had its price target raised by analysts at Raymond James from $144.00 to $146.00. They now have an "outperform" rating on the stock.
11/5
01:49 pm
rvty
Revvity, Inc. (NYSE: RVTY) had its price target lowered by analysts at Sanford C. Bernstein from $150.00 to $145.00. They now have an "outperform" rating on the stock.
Low
Report
Revvity, Inc. (NYSE: RVTY) had its price target lowered by analysts at Sanford C. Bernstein from $150.00 to $145.00. They now have an "outperform" rating on the stock.
11/5
08:17 am
rvty
Revvity, Inc. (NYSE: RVTY) had its price target raised by analysts at Robert W. Baird from $136.00 to $138.00. They now have an "outperform" rating on the stock.
Low
Report
Revvity, Inc. (NYSE: RVTY) had its price target raised by analysts at Robert W. Baird from $136.00 to $138.00. They now have an "outperform" rating on the stock.
11/4
06:00 am
rvty
Revvity Announces Financial Results for the Third Quarter of 2024
Medium
Report
Revvity Announces Financial Results for the Third Quarter of 2024
10/24
04:05 pm
rvty
Revvity Board Declares Quarterly Dividend
Low
Report
Revvity Board Declares Quarterly Dividend
10/22
09:00 am
rvty
Revvity Introduces Transcribe AI: Revolutionizing Data Entry in Clinical Laboratories
Low
Report
Revvity Introduces Transcribe AI: Revolutionizing Data Entry in Clinical Laboratories
10/22
08:00 am
rvty
Revvity Highlights its Strong Progress on Sustainability and Workplace Culture in 2024 Impact Report
Low
Report
Revvity Highlights its Strong Progress on Sustainability and Workplace Culture in 2024 Impact Report
10/17
11:36 am
rvty
Revvity, Inc. (NYSE: RVTY) had its price target raised by analysts at Leerink Partners from $130.00 to $135.00. They now have an "outperform" rating on the stock.
Low
Report
Revvity, Inc. (NYSE: RVTY) had its price target raised by analysts at Leerink Partners from $130.00 to $135.00. They now have an "outperform" rating on the stock.
10/15
07:56 am
rvty
Revvity, Inc. (NYSE: RVTY) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating. They now have a $140.00 price target on the stock, up previously from $125.00.
Low
Report
Revvity, Inc. (NYSE: RVTY) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating. They now have a $140.00 price target on the stock, up previously from $125.00.
10/7
08:00 am
rvty
Revvity To Hold Earnings Call on Monday, November 4, 2024
Low
Report
Revvity To Hold Earnings Call on Monday, November 4, 2024
10/2
08:00 am
rvty
Revvity's EUROIMMUN Launches Solution for Specific Typing of Alzheimer's Disease Associated APOE Gene
Low
Report
Revvity's EUROIMMUN Launches Solution for Specific Typing of Alzheimer's Disease Associated APOE Gene
8/27
06:30 pm
rvty
Revvity, Inc. (NYSE: RVTY) is now covered by analysts at Wells Fargo & Company. They set an "equal weight" rating and a $130.00 price target on the stock.
Low
Report
Revvity, Inc. (NYSE: RVTY) is now covered by analysts at Wells Fargo & Company. They set an "equal weight" rating and a $130.00 price target on the stock.